News in SMBS
02/09/12 In the following Q&A, David G. Lichter, MD, professor of neurology in the University at Buffalo School of Medicine and Biomedical Sciences and an expert in movement disorders, including Tourette's Syndrome and other tic disorders, discusses the emergence of conversion disorder in high school girls in LeRoy, New York and what might be causing it. He has been interviewed on the topic by numerous local and national media.
UB Ranked Among 'Best Values for 2012' By Princeton Review
02/07/12 The University at Buffalo is among the nation's top 75 "best value" public colleges and universities, according to The Princeton Review's annual national survey of American colleges and universities.
Parkinson's Disease: Study of Live Human Neurons Reveals the Disease's Genetic Origins, New Drug Targets
02/07/12 Parkinson's disease researchers at the University at Buffalo have discovered how mutations in the parkin gene cause the disease, which afflicts at least 500,000 Americans and for which there is no cure.
UB's New Medical Research Building Will Benefit Patients and the Region
02/02/12 The stage is set for some important medical advances at the University at Buffalo's Clinical and Translational Research Center (CTRC). The new UB facility will be housed in the top four floors of the new $291 million joint UB-Kaleida Health building now under construction at Goodrich and Ellicott streets on the Buffalo Niagara Medical Campus.
UB, Women and Children's Hospital Played Key Role in Development of new Cystic Fibrosis Drug Approved by FDA
01/31/12 The Cystic Fibrosis Therapeutics Development Center of the University at Buffalo and Women and Children's Hospital of Buffalo played a critical role in the development of the new breakthrough drug called Kalydeco, which the U.S. Food and Drug Administration approved today for the treatment of a less-common mutation of cystic fibrosis.